Medtronic, Inc. (NYSE:MDT)

Obesity, aging baby boomers, health care emphasis in this year's election all point toward growth for medical device companies. They still have possible litigation from there recent product failure, but they will make up for it in 2-4 years in the current economy.

heart in a bottle

great company, great products, aging nation, can't be beat

This medical device manufacturer ahs been beating expectations over & over again. Have owned this stock for over a year and it has growm by over 40%. Expectations going forward are lower, but still well ahead of the crowd.

Beaten down by the recall and cheap. Will come back.

this company has market share. it's a must in any portfolio.

aging

Fantastic company at awesome valuation currently.

makes all sorts of medical devices. innovative. now at low.. best time to buy, won't get it at these prices again. the negative news will pass.

Bad device news is overdone, valuation is attractive.

Nice entry point after the sell-off. Should come back over time.

The company just hit a bump in the road to saving lives. It will pick up the pieces and make itself better.

I'm going to have to say this is a good buy on the BIG dip near the 52wk low.

Buying opportunity on over reaction to recall of leads. With approval of coated stents in Europe, MDT's looks brighter than when it was at $57.

Recent drop in stock price due to the heart monitor "scare" as well as the overall S&P decline puts this stock at a current good price, should rebound back into the low to mid - 50's, and it pays a dividend.

beaten down stock.

Drop on 10/15/07 related to lead fractures has given a good buying opportunity. This problem could lead to declines in implantable defribrillators over the next year or so, but could also lead to increases in external defibrillators (made by MDT's Physio-Control division). Implantable defibrillators are only a portion of MDT's medical device business. With Pacemakers, insulin pumps, ENT devices, all sorts of catheters, ENT devices, spinal devices, etc., earnings should continue to rise as they have done for years, dividend, though small, should continue to increase, and hopefully, the stock price should eventually follow the earnings and revenues up.

Adding good company on sell off due to lead recall.

Looks like approvals for their latest stent will happen. Also, possible acquisition of Kyphon Inc. (KYPH) looks like a good move.